Detalles de la búsqueda
1.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 28(1): 128-135, 2017 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28177460
2.
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Ann Oncol
; 26(7): 1494-500, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25851628
3.
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol
; 26(2): 313-20, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403582
4.
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Ann Oncol
; 25(1): 81-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24273046
5.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 30(6): 1018, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30624555
6.
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto).
Ann Oncol
; 25(12): 2363-2372, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25223482
7.
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Ann Oncol
; 24(2): 398-405, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23047045
8.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Ann Oncol
; 24(3): 618-24, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23136233
9.
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Ann Oncol
; 24(9): 2316-24, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23661292
10.
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Ann Oncol
; 24(8): 1980-5, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23567146
11.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 29(10): 2152, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29701764
12.
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Ann Oncol
; 24(11): 2786-93, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23970015
13.
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Ann Oncol
; 24(12): 2978-84, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24136883
14.
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Br J Cancer
; 107(6): 956-60, 2012 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22892393
15.
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
Ann Oncol
; 22(2): 301-6, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20624784
16.
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Ann Oncol
; 21(11): 2188-2194, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20444845
17.
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
Ann Oncol
; 19(2): 292-8, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17846019
18.
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
J Clin Oncol
; 19(15): 3506-15, 2001 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11481357
19.
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Eur J Cancer
; 40(7): 988-97, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15093573
20.
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Semin Oncol
; 26(3 Suppl 9): 24-31, 1999 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-10426456